INTRODUCTION
Melanoma is one of the deadliest type of skin cancer, with a dismal 5-year survival rate for patients with metastatic melanoma. However, in the last decade, the development of novel immune therapy and targeted therapy has significantly improved overall survival in patients with advanced melanoma, and these therapies have replaced cytotoxic chemotherapy as the mainstay of systemic treatment. Checkpoint inhibitors, such as anti CTLA-4 and antiePD-1 antibodies, have shown durable tumor control among responders and have emerged as the front-line therapies in the treatment of metastatic melanoma.
The co-inhibitory checkpoint receptor molecule PD-1 is highly expressed on T lymphocytes. When PD-1 binds to its ligands (PD-L1 and PD-L2), it inhibits T-cell activation and proliferation in the tumor microenvironment. 1 Therefore, PD-1 binding to its ligands ultimately results in immune suppression against cancer cells. Nivolumab is an antiePD-1 antibody that disrupts the binding of PD-1 to its ligands and restores T-cell activation and the body's immunologic response to cancer cells. It has demonstrated superior clinical efficacy, including significant improvements in overall survival and progression-free survival over antieCTLA-4 antibody and cytotoxic chemotherapy drugs. 2, 3 Common side effects associated with nivolumab include fatigue, nausea, and diarrhea but, more importantly, immune-related adverse events such as dermatitis, colitis, hepatitis, and endocrinopathies. 2 Here we describe a case of granulomatous panniculitis mimicking disease progression in a patient with metastatic melanoma who was treated with nivolumab.
CASE REPORT
The patient was a 66-year-old man with a 1.15-mm thick, nonulcerated primary melanoma on the upper back diagnosed in October 2011 who had undergone wide local excision and left axillary sentinel lymph node dissection, revealing 1 lymph node positive for metastatic melanoma. In May 2015, he had a locoregional recurrence with 3 new hypermetabolic subcutaneous metastases in the left axilla and the left upper back confirmed by cytology. His tumor did not harbor a BRAF mutation. He started treatment with a combination of ipilimumab and nivolumab in July 2015. A positron emission tomography (PET)/computed tomography (CT) scan of the body in September 2015 showed resolution of the subcutaneous nodules in the left axilla. However, after 2 doses, a grade 3 diffuse papular skin rash and grade 3 hepatitis developed, and the combination therapy was discontinued. After his rash and hepatitis resolved with corticosteroid treatment, he started treatment with nivolumab alone in September 2015, without recurrence of the severe rash or hepatitis.
In December 2015, a PET/CT scan showed ill-defined subcutaneous fat stranding in the medial left lower extremity, without apparent skin abnormalities on physical examination. In January 2016, he presented with small skin nodules in the left calf that were mildly tender to palpation. In March 2016, he noted an increasing number of diffuse erythematous nontender subcutaneous nodules on his bilateral lower extremities (Fig 1, A) . A PET/CT scan at that time showed interval development of approximately 50 hypermetabolic subcutaneous nodules in the upper extremities, pelvis, and lower extremities, mostly concentrated in the lower extremities below the knees (Fig 1, B) , raising a high suspicion for disease progression in the subcutaneous tissue. Results of blood tests at the time showed elevated erythrocyte sedimentation rate at 100 mm/h (normal range, 0-20 mm/h), slightly elevated rheumatoid factor at 17 IU/mL (normal, \15 IU/mL), and C-reactive protein at 9.0 mg/L (normal, 0-8.0 mg/L). Complete blood counts, liver function results, and serum creatinine level were within normal limits, and antinuclear antibody titer was negative. Excisional biopsy of 3 of the subcutaneous nodules on his lower extremities and the forearm found a robust lobular, septal, and paraseptal lymphohistiocytic infiltrate that was overtly granulomatous in nature in some areas in which multinucleate histiocytes were noted. No vasculitis was observed, and no bacterial, fungal, or mycobacterium tuberculosis DNA was detected in the samples. On the basis of pathologic evaluation, a diagnosis of granulomatous panniculitis was made.
Nivolumab treatment was discontinued at the time of panniculitis diagnosis, and the patient was observed clinically without corticosteroid treatment. However, by May 2016, an increasing number of subcutaneous lesions developed throughout his body, more prominently in the lower legs. Although some of the existing lesions had resolved, some of the lesions became tender. C-reactive protein was further elevated (36.1 mg/L), but erythrocyte sedimentation rate was normal. A PET/CT scan showed further progression of the subcutaneous nodules throughout the body. He was started on 20 mg of oral prednisone daily, and his subcutaneous nodules regressed quite rapidly. Prednisone was slowly tapered off over the next 3 months. A follow-up PET/CT scan performed in August 2016 showed near complete resolution of the subcutaneous lesions.
DISCUSSION
Panniculitis, inflammation of the subcutaneous fat, is a relatively rare condition that is generally associated with infection, trauma, malignancy, or inflammatory states. The diagnosis of panniculitis can be difficult to make on physical examination, as the subcutaneous nodules or plaques can resemble other conditions, such as vasculitis or tumors. Although a presumptive diagnosis is frequently made clinically, histologic evaluation is required for a definitive diagnosis. Histologic assessment is especially valuable when malignant conditions, such as metastatic cancers or subcutaneous lymphomas, need to be excluded and distinguished from panniculitis, such as in our patient. Although the exact pathophysiology is unknown, panniculitis is generally considered a type IV delayed hypersensitivity cellular reaction primarily to viruses, bacteria, fungi, or other antigens. The reaction is lymphohistiocytic in part, and granuloma formation is a natural end product of a heightened cellular immune response. 4 In our case, the finding of the erythematous skin nodules showed a lobular, septal, and paraseptal lymphohistiocytic infiltrate that was overtly granulomatous in nature, with the presence of multinucleate histiocytes (Fig 2, A and B) . The findings were reminiscent of those of erythema nodosum, the most common type of panniculitis, which typically involves inflammation of the septa in the subcutaneous tissue, usually without associated vasculitis. 5 However, our sample involved lobular, septal, and paraseptal lymphohistiocytic infiltrates and was not limited to the septa as in erythema nodosum. Furthermore, our patient had nodules extending from his lower extremities to his trunk and upper extremities, and erythema nodosum is typically confined to the lower legs. Our patient also did not have fever or arthralgia, which are commonly associated with erythema nodosum. Lipodermatosclerosis/sclerosing panniculitis, another subtype of panniculitis, is typically confined to the lower extremities and is not granulomatous. Therefore, a diagnosis of erythema nodosum-like granulomatous panniculitis was favored. Corticosteroids can be used successfully to treat panniculitis, as demonstrated in our case.
It is possible to speculate that the granulomatous inflammatory reaction in the skin in our patient is a part of sarcoidosis induced by the treatment. In fact, sarcoidosis has been observed in patients who were treated with the checkpoint inhibitor therapy. 6, 7 Although it is difficult to distinguish granulomatous panniculitis from subcutaneous sarcoidosis, as both conditions have very similar clinical and pathologic characteristics, most cases of subcutaneous sarcoidosis have the granulomatous inflammations concurrently in other organs, most commonly in the lymph nodes and lungs. It is rare to observe such reaction only in the skin without other involved organs. To date, there have been only 2 reported cases of sarcoidosis only in the skin/dermis, which occurred during the checkpoint inhibitor treatment. 6, 7 Although our patient's diagnosis may also be a rare case of subcutaneous sarcoidosis, we believe that granulomatous panniculitis is a more precise term for out patient's condition.
For our patient, infection was ruled out with DNA probes for acid-fast bacilli, fungi, and bacteria.
Because he had had no other changes in his chronic medications except for the checkpoint inhibitor treatment, we believe his panniculitis was most likely related to nivolumab treatment. To date, there are no reports of granulomatous panniculitis associated with antiePD-1 antibody therapy. Although the patient also received ipilimumab as a part of the combination regimen at the beginning of the therapy, the last dose of ipilimumab was given 7 months before the clinical onset of panniculitis; therefore, ipilimumab is a less likely contributor. However, it is possible that long-lasting T-cell activation induced by ipilimumab could have contributed to overreaction of the T cell response to the subcutaneous tissue.
There have been case reports of a panniculitislike reaction in patients who were treated with BRAF inhibitors including vemurafenib and dabrafenib. 8, 9 These were accompanied by mild fevers and arthralgia as part of a presumed inflammatory reaction. Histologically, most of these lesions had a neutrophilic infiltrate with lobular involvement. 8, 9 In another case series, erythema nodosum (septal infiltrates) and lymphocytic inflammation were noted as a response to a BRAF inhibitor therapy. 10 In addition, KIT inhibitors, such as imatinib and dasatinib, have also been associated with druginduced neutrophilic lobular panniculitis. 11 These findings suggest the heterogeneity of drug-induced panniculitis with varying pathophysiology.
Here we report the rare case of granulomatous panniculitis induced by antiePD-1 antibody therapy. Because the clinical manifestation and radiologic findings of diffuse panniculitis closely mimic recurrence or progression of malignancy while a patient is undergoing antiePD-1 antibody therapy, clinicians should consider biopsy of new suspicious skin nodules to distinguish the inflammatory reaction from malignancies, especially when there is no evidence of disease progression in noncutaneous organs. Corticosteroids can be used to treat the inflammation with good results.
